Baseline means (SD) | Changes from baseline to end of program Means (SD) | p Value* | Changes from baseline to 24-month follow-up Means (SD) | p Value | |
Weight (kg) | |||||
Women | 83.0(12.4) | -1.0(3.9) | 0.22 | -1.4 (5.8) | 0.22 |
Men | 97.2(11.9) | -0.3(3.4) | 0.68 | - 0.9 (6.3) | 0.53 |
BMI (kg/m2) | |||||
Women | 30.3(4.2) | -0.4(1.4) | 0.21 | -0.6 (2.1) | 0.21 |
Men | 29.9(2.8) | -0.1(1.1) | 0.72 | -0.2(1.9) | 0.59 |
Waist circumference (cm) | |||||
Women | 102.4(9.5) | -2.7(3.9) | 0.001* | -4.0(5.4) | 0.001* |
Men | 107.1(6.1) | -0.5(3.8) | 0.60 | -1.7(6.2) | 0.20 |
FINDRISC Score | |||||
Women | 16.8(2.6) | -1.1(2.8) | 0.08 | -1.2(3.2) | 0.09 |
Men | 16.3(3.8) | +0.5(2.8) | 0.36 | -0.2(2.8) | 0.69 |
HbA1c (mmol/mol) | |||||
Women | 5.8(0.3) | -0.2(0.2) | 0.001* | --0.2 (0.02) | 0.001* |
Men | 6.0(0.6) | -0.2(0.2) | 0.001* | -0.2(0.4) | 0.03** |
Fasting blood glucose(mg/dL) | |||||
Women | 5.6(0.7) | -0.2(0.6) | 0.18 | -0.1(0.5) | 0.24 |
Men | 5.9(1.3) | +0.0(0.6) | 0.44 | +0.3(0.4) | 0.03** |
Total cholesterol (mg/dL) | |||||
Women | 5.4(0.9) | +2.0(0.6) | 0.001* | +0.1(0.8) | 0.42 |
Men | 4.9(1.1) | +1.5(0.5) | 0.001* | -0.2(0.6) | 0.25 |
HDL cholesterol (mg/dL) | |||||
Women | 1.8(0.9) | -0.2(0.9) | 0.06 | -0.2(0.9) | 0.86 |
Men | 1.3(0.3) | 0.0(0.1) | 0.95 | 0.0(0.1) | 0.95 |
LDL cholesterol (mg/dL) | |||||
Women | 3.3(1.1) | 0.0(0.4) | 0.81 | +0.2(0.8) | 0.19 |
Men | 3.1(1.0) | -0.2(0.4) | 0.06 | -0.1(0.6) | 0.68 |
Triglycerides (mg/dL) | |||||
Women | 1.2(0.5) | +0.1(0.5) | 0.93 | +0.2(0.4) | 0.06 |
Men | 1.3(0.7) | -0.1(0.3) | 0.14 | +0.1(0.2) | 0.13 |
COOP/WONKA Physical activities as hard | |||||
Women | 23.1% | -0.1(0.4) | 0.13 | +0.1(0.5) | 0.78 |
Men | 42.1% | -0.1(0.6) | 0.28 | +0.0(0.6) | 0.63 |
COOP/WONKA Overall health as good | |||||
Women | 76.9% | +0.1(0.5) | 0.41 | 0.0(0.6) | 0.71 |
Men | 52.6% | -0.2(0.5) | 0.18 | -0.1(0.5) | 0.10 |
COOP/WONKA Health impact on social activities | |||||
Women | 19.2% | 0.0(0.4) | 1.00 | +0.1(0.4) | 0.32 |
Men | 0.0% | +0.1(0.2) | 0.32 | +0.1(0.2) | 0.32 |
** Significant p<0.05.
*Significant p<0.002.
Wilcoxon test used.
BMI, body mass index; FINDRISC, Finnish Diabetes Risk Score; HDL, high-density lipoprotein.